To test whether TIGIT signaling blockade can reinvigorate T cell responses in patients with pancreatic cancer, we added anti-TIGIT Ab to in vitro T cell cultures using PBMCs from a pancreatic cancer patient treated with a polyepitope neoantigen DNA vaccine on an expanded access protocol. The gene discussed is TIGIT; the disease is familial pancreatic carcinoma.